Effectiveness of suprapubic temperature stimulation for postoperative urinary retention: a systematic review and meta-analysis protocol Authors: Xiaoting Wang, Shumin Wu, Liying Zhang Published: 2026 ABSTRACT Abstract AbstractIntroductionPostoperative urinary retention (POUR) is a common perioperative complication that can cause delayed mobilisation and discharge, and increase the need for catheterisation. Suprapubic temperature stimulation is a simple bedside, nurse-led approach but its effectiveness and safety have not been synthesised in a focused review.Methods and analysisWe will systematically search PubMed, Embase, CINAHL, PsycINFO, Web of Science and CENTRAL from inception to the final search date, without language or date restrictions and will also screen trial registries and grey literature. We will include randomised controlled trials evaluating suprapubic temperature stimulation for prevention or treatment of POUR, compared with usual care, sham/no intervention or other non-thermal strategies. Two reviewers will independently screen studies, extract data and assess risk of bias using RoB 2, with arbitration by a third reviewer. Where appropriate, we will pool effects using ORs for dichotomous outcomes and mean differences or standardised mean differences for continuous outcomes, each with 95% CIs. Heterogeneity will be assessed using the χ2 test and I2 statistic, with planned subgroup analyses by thermal modality and timing, and sensitivity analyses based on risk of bias. Certainty of evidence will be appraised using the Grading of Recommendations Assessment, Development and Evaluation.Ethics and disseminationThis review will be based on previously published studies; therefore, ethics approval is not required. Data searching will commence in June 2026 and is expected to be completed in January 2027. The findings will be disseminated through peer-reviewed journal publication and academic conference presentations.PROSPERO registration numberCRD420261325021.Keywords: Nursing Care, Neuro-urology, Patient Reported Outcome Measures, Patient Care Management STRENGTHS AND LIMITATIONS OF THIS STUDY This review will systematically search major biomedical databases, trial registries and grey literature sources, supplemented by manual screening of reference lists from included studies and relevant reviews. This review will systematically search major biomedical databases, trial registries and grey literature sources, supplemented by manual screening of reference lists from included studies and relevant reviews. The review will include only randomised controlled trials, without restrictions on language or publication date. The review will include only randomised controlled trials, without restrictions on language or publication date. The protocol will follow Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidance and use duplicate study selection, data extraction, risk-of-bias assessment and Grading of Recommendations Assessment, Development and Evaluation to enhance methodological rigour. The protocol will follow Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidance and use duplicate study selection, data extraction, risk-of-bias assessment and Grading of Recommendations Assessment, Development and Evaluation to enhance methodological rigour. Variations in surgical populations, anaesthetic techniques, perioperative pathways and catheterisation thresholds across trials may affect the consistency of data synthesis. Variations in surgical populations, anaesthetic techniques, perioperative pathways and catheterisation thresholds across trials may affect the consistency of data synthesis. Differences in intervention parameters, postoperative urinary retention definitions and outcome timing may limit comparability and meta-analysis feasibility. Differences in intervention parameters, postoperative urinary retention definitions and outcome timing may limit comparability and meta-analysis feasibility. Introduction Postoperative urinary retention (POUR) is commonly defined as the inability to void despite a full bladder after surgery and anaesthesia, although operational definitions vary across studies and settings.1,4 This variability, together with differences in surgical procedures, analgesic regimens and anaesthetic techniques, is reflected in a wide reported incidence range (approximately 5%–70%), with some fast-track orthopaedic pathways reporting particularly high rates and substantial between-centre variation.5 POUR is clinically important because it is not merely an inconvenience: untreated retention can lead to painful bladder overdistension, marked discomfort and delayed mobilisation, and may contribute to prolonged hospitalisation and downstream complications.6 Contemporary surgical cohorts further suggest that POUR can drive unplanned admissions and readmissions and is associated with complications such as suspected urinary tract infection (UTI) and acute kidney injury in some patients.7 Taken together, POUR is a common, perioperative complication that is potentially preventable and treatable, and there remains a clear need for effective, easy-to-implement strategies that support early recovery of spontaneous voiding. Current management typically involves stepwise assessment and bladder emptying strategies, including observation and voiding facilitation, bedside bladder ultrasound to assess bladder volume/post-void residual (PVR) and bladder decompression via intermittent or indwelling urethral catheterisation when indicated.5 However, these approaches present persistent challenges in practice. Catheterisation can be distressing and uncomfortable, and it carries recognised risks including UTI, urethral trauma and other catheter-related morbidity.8,10 In addition, the bladder volume threshold or clinical criteria that should trigger catheterisation are not standardised and remain uncertain, contributing to inconsistent pathways and possible unnecessary catheter use across departments.11 Pharmacological options and other invasive measures may be limited by contraindications, adverse effects or feasibility in routine care. Consequently, low-cost, low-risk, nurse-led non-invasive interventions that can be delivered at the bedside are of high practical value. Suprapubic (bladder-region) temperature stimulation is a simple, externally applied intervention that typically includes warm compresses/hot packs, cold compresses/ice packs or alternating hot-cold applications over the suprapubic area. It is clinically feasible, requires minimal equipment and has potential for protocolisation (eg, specifying temperature range, duration, frequency and timing). The mechanism is not fully established, but it is plausible that thermal stimulation may modulate cutaneous sensory input and comfort, reduce anxiety-related pelvic floor tension or reflex sphincter spasm and facilitate initiation of the micturition reflex, thereby supporting bladder emptying. Randomised and clinical trial evidence has explored suprapubic hot packs or warm water-soaked gauze as treatments for established POUR, with some studies reporting reduced need for catheterisation compared with usual care.12 More recent and ongoing studies have expanded the scope to cold or hot-cold applications, but populations, methods (eg, temperature, duration, frequency) and outcomes (eg, time to first void, PVR volume) differ across trials, and findings are not fully consistent.13,15 Despite increasing interest, the evidence base for suprapubic temperature stimulation remains dispersed within broader POUR reviews that synthesise heterogeneous interventions, meaning the overall effectiveness and the circumstances under which it is most useful are still unclear. Although suprapubic temperature stimulation is occasionally described as a bedside option to facilitate voiding, the supporting evidence is scattered across broader POUR management literature with variable definitions and inconsistent outcome reporting, making its independent effect difficult to quantify.16,18 Therefore, a focused systematic review and, where feasible, meta-analysis is warranted to quantify the effectiveness and safety of suprapubic temperature stimulation for POUR, and to explore potential sources of heterogeneity and applicability. The present protocol outlines methods to evaluate key outcomes, including the proportion requiring catheterisation, time to first spontaneous void, PVR volume, recurrence of retention and adverse events; where pooling is not appropriate, findings will be synthesised narratively. Materials and methods Protocol registration and reporting This protocol has been prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO) (registration number: CRD420261325021). It was prepared in line with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 guidance, and the completed PRISMA-P checklist is provided in online supplemental S1 file.19 Any substantive changes made after registration (eg, to eligibility criteria, outcomes or analytical methods) will be dated, justified and updated in the PROSPERO record, and will also be transparently reported in the final systematic review and meta-analysis. Search strategy and information source The search strategy will be developed by the review team, with input from an information specialist where available. We will conduct comprehensive searches from database inception to the date of the final search in PubMed (MEDLINE), Embase, CINAHL, PsycINFO, Web of Science and the Cochrane Central Register of Controlled Trials (CENTRAL), without restrictions on publication date or language. Non-English records will be screened using translated titles and abstracts where available, and potentially eligible full texts will be translated with professional translation support, language-proficient reviewers or validated translation tools, with key eligibility and extraction decisions checked by two reviewers. Search concepts will be built around (1) POUR (and related terms such as urinary retention, bladder overdistension, PVR) and (2) suprapubic/bladder-region temperature stimulation (eg, warm/heat compress or hot pack, cold compress or ice pack and hot-cold alternating applications). We will combine subject headings and keywords using Boolean operators, adapting the syntax to each database. Database search strategies are detailed in online supplemental S2 file. To minimise publication bias, we will also search grey literature sources and trial registries, including ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform, to identify ongoing or unpublished studies. We will screen the reference lists of included studies and relevant reviews and, where necessary, conduct citation searching and targeted hand-searching to identify additional eligible studies. We will contact the study authors for clarification or missing information where necessary. Eligibility criteria Population We will include postoperative patients of any sex and age who undergo surgery under any type of anaesthesia and are at risk of, or diagnosed with, POUR in the post-anaesthesia care unit or on surgical wards. Studies will be eligible irrespective of surgical specialty and setting. We will exclude studies focused primarily on patients with pre-existing chronic urinary retention, neurogenic bladder, urinary diversion or routine preoperative catheterisation where postoperative voiding recovery is not assessable. Intervention We will include studies evaluating suprapubic temperature stimulation applied to the bladder region, including warm or hot stimulation, cold stimulation and alternating hot-cold stimulation delivered after surgery for prevention or treatment of urinary retention. To be eligible, studies must report at least the thermal modality and the application site and should provide, where available, key intervention parameters including temperature or target range, duration, frequency, timing and delivery method. Studies in which the intervention cannot be identified as a suprapubic thermal application will be excluded. Studies with partially reported parameters will not be excluded solely for incomplete reporting but will be recorded as having incomplete intervention description and considered in sensitivity or narrative analyses where appropriate. Studies will be eligible when the temperature stimulation is used alone or alongside usual care, as long as cointerventions are applied equally across groups. Comparison Eligible comparators will include routine postoperative care without suprapubic temperature stimulation, sham or placebo procedures, no intervention or other non-thermal strategies intended to facilitate voiding. Studies comparing different temperature regimens, such as warm vs cold or alternating versus single-modality application, will also be included when relevant. Outcomes The primary outcomes will be the proportion of participants requiring catheterisation and the incidence of POUR as defined by each study. Secondary outcomes will include time to first spontaneous void, PVR volume, recurrence of retention after initial voiding and adverse events related to the intervention, such as skin injury, pain or intolerance. We will accept any validated or study-defined outcome measures and any follow-up time points. For POUR incidence and catheterisation-related outcomes, we will extract the operational definition used in each study, including bladder volume thresholds, PVR criteria, inability-to-void criteria, symptom-based criteria, time since surgery or catheter removal and the clinical indication for catheterisation. Study design We will include randomised controlled trials, including individual and cluster randomised designs, that assess suprapubic temperature stimulation for POUR. We will exclude non-randomised studies, qualitative research, case reports, reviews, guidelines, editorials and animal studies. Conference abstracts will be considered only if sufficient outcome data are available for appraisal and synthesis. Study selection All records identified through the searches will be imported into EndNote for reference management and duplicate records will be removed using Rayyan. After de-duplication, XW and SW will independently screen titles and abstracts against the eligibility criteria and exclude clearly irrelevant studies. Full texts will be retrieved for all potentially eligible reports and assessed independently by the same two reviewers to determine final inclusion. Any disagreements will be resolved through discussion; if consensus cannot be reached, LZ will review the evidence and make the final decision. Reasons for exclusion at the full-text stage will be documented. The study selection process will be presented in online supplemental S1 figure in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement.20 Data extraction Data will be extracted from all included studies independently by XW and SW using a standardised, purpose-built data extraction form informed by the Cochrane Handbook. Discrepancies will be resolved through discussion, and unresolved cases will be adjudicated by LZ. We will extract study characteristics including author, year, country, setting, design and methods of randomisation and blinding; participant information including sample size, age, type of surgery and anaesthesia, baseline risk factors and relevant exclusion criteria; intervention and comparator details including modality, temperature or target range, duration, frequency, timing, cointerventions and follow-up; and outcome data including operational definitions of POUR, bladder volume or PVR thresholds, catheterisation criteria, measurement time points and effect estimates for catheterisation requirement, time to first spontaneous void, PVR volume, recurrent retention and adverse events. When outcome data are incomplete, we will contact the corresponding authors to obtain additional information. Risk of bias assessment Risk of bias in included randomised trials will be assessed independently by XW and SW using the revised Cochrane risk-of-bias tool for randomised trials (RoB 2).21 The assessment will cover bias arising from the randomisation process, bias due to deviations from intended interventions, bias due to missing outcome data, bias in measurement of the outcome and bias in selection of the reported result. Each domain and an overall judgement for each key outcome will be rated as low risk of bias, some concerns or high risk of bias. Any disagreements will be resolved through discussion, and if consensus cannot be reached, LZ will adjudicate. The results will be summarised in tables and figures and will inform sensitivity analyses and interpretation of findings. Certainty of evidence assessment The certainty of evidence for each primary and key secondary outcome will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.22 The body of evidence will be rated as high, moderate, low or very low after considering risk of bias, inconsistency, indirectness, imprecision and publication bias. The assessment will be conducted independently by XW and SW, with disagreements resolved through discussion and, when needed, adjudicated by LZ. We will summarise the judgements and key effect estimates in a Summary of Findings table for outcomes such as catheterisation requirement, time to first spontaneous void, PVR volume and adverse events. Data synthesis Meta-analysis will be undertaken only when studies address the same clinically interpretable comparison and are sufficiently comparable in terms of clinical context, intervention purpose, comparator conditions and outcome definitions. Before pooling, we will first examine whether studies can be grouped into clinically coherent comparison sets, such as preventive use vs therapeutic use, warm or hot stimulation vs usual care, cold stimulation versus usual care or alternating hot-cold stimulation vs usual care. Intervention categories will be defined a priori as warm or hot stimulation, cold stimulation and alternating hot-cold stimulation. Within each category, we will summarise key parameters, including temperature or target range, duration, frequency, timing and delivery method. Studies will not be combined in a single meta-analysis if they differ in ways that make a common effect estimate clinically uninterpretable, for example, when preventive and therapeutic applications, substantially different thermal modalities, incompatible POUR definitions or non-comparable catheterisation criteria cannot be separated into meaningful groups. In such situations, findings will be synthesised narratively rather than statistically pooled. POUR definitions will be categorised according to the operational criteria used in the original studies, such as bladder volume or PVR thresholds, inability to void within a specified postoperative period, symptom-based criteria or composite definitions; catheterisation criteria will be categorised according to the reported trigger thresholds or clinical indications. If statistical pooling is not appropriate, we will synthesise findings narratively using a structured approach and report the results in line with the Synthesis Without Meta-analysis guidance. For dichotomous outcomes such as catheterisation requirement and study-defined POUR incidence, we will calculate pooled ORs with 95% CIs using the Mantel-Haenszel method. For continuous outcomes such as time to first spontaneous void and PVR volume, we will use a mean difference when outcomes are measured on the same scale, or a standardised mean difference when scales differ, and report 95% CIs. When the same outcome is reported at multiple time points, only one time point from each study will be included in a single meta-analysis. We will use the time point most commonly reported across studies and summarise other time points separately where possible. A two-tailed p value below 0.05 will be considered statistically significant. Before pooling, statistical heterogeneity will be assessed using the χ² test and the I² statistic. We will interpret I² values as follows: below 25% no heterogeneity, 25%–49% low heterogeneity, 50%–74% moderate heterogeneity and 75% or above high heterogeneity.23 The choice between fixed-effect and random-effects models will be based on both statistical heterogeneity and clinical or methodological considerations, including similarity of surgical populations, anaesthetic context, intervention modality, intervention parameters, comparator conditions and outcome definitions. A fixed-effect model will be used when studies are sufficiently similar and heterogeneity is low. A random-effects model will be used when clinically plausible between-study variation is expected or when moderate statistical heterogeneity is present. If heterogeneity is substantial and cannot be clinically explained or addressed through appropriate grouping, we will not present a single pooled estimate and will use narrative synthesis instead. If meta-analysis is appropriate within a clinically coherent comparison set and sufficient studies are available, we will explore residual heterogeneity through subgroup analyses according to prespecified factors, including temperature modality, timing or purpose of use, surgical or anaesthetic context, POUR definition and bladder volume thresholds. If at least 10 studies are available for a given outcome within an appropriate comparison set, we will consider meta-regression to examine whether study-level characteristics explain between-study heterogeneity. Meta-regression will be considered exploratory and interpreted cautiously because it may be underpowered and subject to ecological bias. Sensitivity analyses will be performed to examine robustness by excluding studies at unclear or high risk of bias and by assessing the influence of key analytical choices. If at least 10 studies are available for an outcome, publication bias will be explored using funnel plot asymmetry and Egger’s test.24 Patient and public involvement Patients and the public were not involved in the development of this protocol. This study is a systematic review of published literature and will not collect primary data from patients. Discussion Burden of POUR and rationale for this study POUR remains a frequent and clinically meaningful complication after surgery and anaesthesia, contributing to patient distress and potentially avoidable delays in recovery and discharge.25,27 Although bladder decompression is effective, catheter use can itself be burdensome, as catheter-related bladder discomfort is common and characterised by suprapubic pain, urgency and bladder spasms, and agitation related to discomfort may precipitate traumatic catheter removal.28,31 In addition, iatrogenic urethral catheterisation injury is a recognised source of patient morbidity and service burden, reported both in classic inpatient surveillance and in contemporary multicentre prospective data.32 Against this background, conservative measures such as suprapubic hot packs or warm, moist compresses are often mentioned as simple bedside options, yet the underlying trials are limited and frequently use non-standard definitions and heterogeneous outcome reporting, making it difficult to isolate the independent effect of thermal stimulation. These uncertainties underscore the need for a focused synthesis to clarify whether suprapubic temperature stimulation offers a reliable, low-risk adjunct for restoring spontaneous voiding in the postoperative setting. Clinical relevance and anticipated contribution This study is expected to provide practice-relevant evidence on whether suprapubic temperature stimulation can reduce catheterisation and accelerate recovery of spontaneous voiding after surgery. POUR can delay discharge and expose patients to additional harms, including infection risk associated with catheter use, so interventions that safely limit catheterisation align with broader perioperative safety priorities.33 At the same time, perioperative programmes increasingly emphasise structured bladder-care pathways and early catheter removal, yet optimal thresholds and supportive bedside measures remain variable across settings.34,37 By synthesising randomised evidence, our study will quantify effects on clinically important outcomes, including the proportion requiring catheterisation, time to first spontaneous void, PVR volume, recurrent retention and adverse events. It will also explore whether effects differ by thermal modality and clinical context, thereby informing implementable nursing protocols and identifying priorities for future trials. Because suprapubic temperature stimulation is a supportive bedside intervention rather than a definitive bladder-emptying strategy, we anticipate that its effect may be modest and context-dependent. Therefore, effect estimates will be interpreted not only according to statistical significance but also according to clinical relevance, such as whether the intervention meaningfully reduces catheterisation, shortens time to first spontaneous void or improves patient comfort without increasing adverse events. The findings will be interpreted in relation to established POUR management strategies, including bladder scanning protocols, standardised catheterisation thresholds and pharmacological approaches. If the review shows clinically meaningful benefits with no important safety concerns, suprapubic temperature stimulation may be considered as a low-risk adjunct within structured postoperative bladder-care pathways, particularly as a nurse-led measure before catheterisation is required. If effects are small, inconsistent or uncertain, routine use should remain cautious and management should continue to be guided by objective bladder assessment and clinically indicated catheterisation. Methodological rigour and transparency This protocol is designed to maximise transparency and reproducibility, which strengthens the credibility of the eventual findings. Prospective registration in PROSPERO will provide an a priori public record of objectives, methods, and any protocol changes.38 Reporting will follow established guidance for systematic review protocols and reviews, supporting complete and standardised documentation of planned methods and results.19 We will use comprehensive information sources and report database-specific strategies in a reproducible format consistent with search-reporting guidance, which should reduce the risk of missed evidence and improve auditability.39 Study screening and data extraction will be conducted independently by two reviewers with third-reviewer arbitration, and internal validity will be appraised using RoB 2 to provide outcome-level risk-of-bias judgements.21 Finally, we will rate the certainty of evidence with GRADE and, where pooling is not appropriate, present a structured narrative synthesis consistent with the Synthesis Without Meta-analysis guidance, ensuring that conclusions reflect both effect estimates and confidence in the evidence base.40 Limitations and implications for future research Several limitations should be considered when interpreting the findings of this study. First, the available trials are likely to vary in surgical populations and perioperative pathways, and in the delivery of suprapubic temperature stimulation, including the target temperature, duration, frequency and timing, which may introduce clinical heterogeneity and limit the precision of pooled estimates.41 Second, inconsistency in POUR definitions and catheterisation thresholds may directly affect the measured incidence of POUR and the proportion requiring catheterisation, thereby limiting comparability across studies and potentially reducing the clinical validity of pooled estimates. Third, reporting of adverse events related to thermal application may be incomplete, which could constrain conclusions about safety.42 Future studies should standardise POUR definitions and core outcomes, report thermal protocols in full, and test warm, cold and alternating regimens in adequately powered trials. Including patient comfort, resource use and implementation feasibility would better support bedside nursing practice. Supplementary material Footnotes Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2026-118750). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. References Supplementary Materials